KIA
CRBU icon

Kraematon Investment Advisors’s Caribou Biosciences CRBU Stock Holding History

Kraematon Investment Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$16.4K – 85
2024
Q2 		$16.4K Buy
+10,000
New +$32K 0.02% 85

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Kraematon Investment Advisors's CRBU Position: Q3 2024 in Review

Kraematon Investment Advisors sold out of Caribou Biosciences (CRBU) in Q3 2024, closing a stake of 10,000 shares — an estimated $16.4K sold.

Kraematon Investment Advisors first reported a position in CRBU in Q2 2024 and held it in 1 quarter. The position peaked at $16.4K in Q2 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

  • Kraematon Investment Advisors reported no remaining Caribou Biosciences position as of Q3 2024 after selling out during the quarter.
  • Kraematon Investment Advisors sold 10,000 Caribou Biosciences shares in Q3 2024, an estimated $16.4K.
  • Kraematon Investment Advisors first reported a position in Caribou Biosciences in Q2 2024 and held it in 1 quarter.
  • Kraematon Investment Advisors's Caribou Biosciences position peaked at $16.4K in Q2 2024.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Kraematon Investment Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.